Printer Friendly

Medicamentos cardiovasculares en la nocicepcion mecanica humana: digoxina, amlodipina, propranolol, pindolol y atenolol.

Cardiovascular drugs in human mechanical nociception: digoxin, amlodipine, propranolol, pindolol and atenolol.

INTRODUCTION

Calcium channel blockers, [beta] adrenergic receptors blockers, and Na/K ATPase inhibitors are widely administered for hypertension, arrhythmia or heart failure, respectively. Neuronal membranes of nociceptive system structures express similar receptors (1), channels (2-5) and ionic pumps (6-8), suggesting potential effects on clinical nociception.

Neurotransmitter release involved in nociception depends on the activation of voltage sensitive calcium channels (2, 4, 9). Calcium channels blockers show anti-nociceptive effects in both, experimental (4, 5) and clinical studies (3), but can also abolish opioid-induced hypersensitivity (10).

The [beta]-adrenergic blockers have a stabilization action on the cellular membranes (11). Propranolol shows a local anesthetic effect similar to lidocaine by decreasing sodium (12) and calcium influxes (13).

During noxious stimulation, nociceptive neurons increase ATPase activity as a countermeasure to sodium influx (14). Acute peripheral inflammation increases not only Na/K-ATPase, but also Na-ATPase and fluoride-resistant acid phosphatase (FRAP) in the ipsilateral spinal dorsal horn, to restore the [Na.sup.+] and [K.sup.+] gradients associated to continued neuronal discharges (14,15) and to reduce the glutamate release (6). These two factors are strongly associated with hyperalgesia and allodynia (7). Digoxin, a Na/K ATPase inhibitor, increases the intracellular concentration of sodium and calcium (16) inducing neuronal depolarization (16), which antagonizes the antinociceptive effect of morphine in mice (17).

It has been proposed that a noxious stimulus can activate various antinociceptive mechanisms, such as diffuse nocicep tive inhibitory control (DNIC) (18), propriospinal antinociceptive responses (19) and descending modulatory system (20) ; however, the action of calcium channels blockers, [beta]-adrenergic blockers and digoxin on these antinociceptive mechanisms has not been extensively analysed.

Despite of a profuse study of basic mechanisms of action of these drugs vide supra, less attention has been paid to acquired pain sensation changes induced in patients taking calcium channels blockers, [beta] adrenergic blockers or ATPase inhibitors therapeutically for cardiovascular diseases and not for pain treatment.

METHODS

The experimental protocol was approved by the Area de Estudios de Postgrado of the Universidad de Carabobo and the Hospital Research Committee of the Social Security Hospital "Dr. Angel Larralde". Informed consent was obtained from patients and volunteers.

Patients

The cross-sectional, randomized sample consisted of patients from the outpatient Internal Medicine Service and by, apparently, healthy volunteers, workers of the same Hospital area. The subjects were grouped according to their drug therapy as follows: [beta] receptors blockers group: with [beta]-blockers treatment, distributed in three subgroups i.e., atenolol, pindolol or propranolol; calcium channels blockers group: with amlodipine; ATPase inhibitor group: with digoxin. Due to the nature of the study, internal controls (pain scores before and after the drug intake) were not possible, hence, a control group was included with apparently healthy, asymptomatic, volunteers without any pharmacological treatment. An interview was performed to confirm their health status.

Subjects included were older than 20 years, of both sexes, who received monotherapy either with [beta]-blockers atenolol, pindolol or propanolol, calcium channel blocker (amlodipine) or cardiac glycoside (digoxin), for more than 6 months and clinically stable. Those patients who had received analgesic drugs 72 hours previous to the study, drank caffeine or smoked tobacco two hours before the test, or those patients with pathologies that affected their sensitive, cognitive, or discriminative capabilities, or those that received pharmacological polytherapy, or those clinically uncompensated, were excluded from the study.

Treatment and measurements

Data were obtained from the clinical history, physical examination, recording of drug dose and values of the Visual Analogical Scale VAS to a calibrated noxious mechanical test. Drugs were administrated in daily oral doses as follows: amlodipine 2.5-10 mg, propranolol 20-600mg, atenolol 25-100 mg, pindolol 5 mg and digoxin 250 [micro]g.

In the outpatient room, a constant noxious pressure gauged to 890 g x [mm.sup.-2] generated by a 2 [mm.sup.2] flat tip spring device was applied for 5 seconds on the sternum's Louis angle of the patient, this midline body location for the stimulus was selected to avoid individual asymmetries in pain sensation (14). The noxious pressure did not induce lesions in the skin. The patient used a vertical Visual Analog Scale VA[S.sub.1], a self reported subjective pain intensity scale. After 5 minutes of resting time, the same stimuli was applied again to evaluate the pain modulation systems, this interval of time was used due to the reported short lasting antinociceptive effects of the first (conditioning) noxious stimulus (18).

Statistics

Values were presented as arithmetic means [+ or -] standard deviations. Distribution of the data was analyzed by the Kolmogorov-Smirnov test. The percentage of difference of VAS values between groups was evaluated by the non parametric Wilcoxon test. Linear regression analysis was performed. Significance level was set at P<0.01.

RESULTS

The study was realized in a total sample of 185 subjects (Table I). Sixty asymptomatic, apparently healthy subjects were included in the control group. The mean age was 48.29 [+ or -] 17.86 years (range 21-86 years), 51.35% of the subjects were male. Arterial hypertension (AH) was present as the sole illness in 85 (68%) patients, which showed blood pressure of 85.2 [+ or -] 3.2 mmHg and 122.4 [+ or -] 4.1 mmHg for diastolic and systolic values respectively, not statistically different to those from the control group (P>0.1). Heart failure (HF) was present in 40 (32%) patients which received digoxin as treatment. The primary cause of HF of this group was arterial hypertension. No age or sex distribution differences were found between control, [beta]-blockers and amlodipine groups (P=0.1). Digoxin group showed higher mean age than the other groups (P = 0.0001; Table I).

Patients in the [beta]-blockers group (n=45; Table II) were distributed according to the drug as follows: atenolol (n=25; 55.6%), pindolol (n=7; 15.6%) and propranolol (n=13; 28.9%). Patients with arterial hypertension showed more than 42% reduction on VAS values when compared with the control group values (Table III) but, patients with heart failure and digoxin treatment showed more than 57% increase on VAS values compared with the control group. HF in patients with AH switches the VAS values from low (negative %) to high pain scores (positive %) from 174 to 212% (Table III).

These three subgroups did not show statistical differences (P=0.13) in age, sex or VAS values distribution, thus, they were grouped together (Table IV).

When comparing the VAS values between the different groups in the [beta]-blockers group presented a 36.8% (P = 0.0000001) reduction in the reported pain intensity when comparing with the control group; the reduction percentage was even higher for the amlodipine group being 50.6% (P=0.0000001) lower than the control group. In contrast, the digoxin group showed and increment up to +56.5% (P=0.0000001) when comparing the VAS values with the control group. The group of patients who received amlodipine showed the strongest reduction of pain intensity values for the mechanical noxious stimulation with -50.6% and -57.8%; P<0.0000001 for VA[S.sub.1] and VA[S.sub.2] respectively (Table IV), less than the control group. The highest differences in pain scores respect to control values were observed in patients who received digoxin showing +56.5% and +58.4% for VA[S.sub.1] and VA[S.sub.2] respectively, higher than the values reported for the control group (P<0.0000001).

The linear regression for the administered dosage of [beta]-blockers and VAS values revealed dose-dependent effects for atenolol (n=25; VA[S.sub.1] r = -0.69; P = 0.00012; VA[S.sub.2] r = -0.61; P=0.0013), but not for propranolol (n=13; VA[S.sub.1] r = -0.46; P = 0.12; VA[S.sub.2] r = -0.31; p = 0.30). No regression analysis was made for pindolol due to the use of only 5 mg dose schedule. The administered dosage of amlodipine was associated inversely to VA[S.sub.1] (n = 40; r = -0.43; P=0.005) and VA[S.sub.2] values (n = 40; r = -0.42; P=0.0074). No regression analysis was made for digoxin due to the use of only 0.25 mg dose schedule. The duration of the treatment was not related to VAS values for the [beta]-blockers (r = 0.18; P = 0.24), amlodipine (r = 0.042; p = 0.80) as well as for the digoxin group (r = 0.22; P = 0.17).

VA[S.sub.2] values were lower than those of VA[S.sub.1] for all groups except for the group who received digoxin. The ranking of pain intensity reduction in VAS scores ([DELTA]VAS) was Control < [beta]-blockers (propranolol, atenolol, pindolol) < calcium blocker (amlodipine) with -6.13%; -16.28% and -23.78% respectively (Table IV). Additionally, [DELTA]VAS values for [beta]-blockers and amlodipine patient groups were statistically more intense than for the control group (P<0.01).

DISCUSSION

The present cross-sectional study evaluated the effect of the therapy of cardiovascular diseases, such as arterial hypertension and/or heart failure with [beta]-blockers, calcium channel blocker or cardiac glycoside on mechanical nociception in 125 patients, compared to 60 healthy volunteers without medication.

It is known that arterial hypertension is associated to hypoalgesia in animals (22, 23) and humans (24). In the present study, the patient group undergoing [beta]-blockers therapy, according to the inclusion criteria, were clinically stable with diastolic and systolic blood pressure values [less than or equal to] 85mmHg and [less than or equal to]123mmHg respectively. There is strong evidence that blood pressure correlates positively with pain thresholds and negatively with pain ratings (23) thus, the lower pain scores respect to control values observed in patients with [beta]-blockers therapy, could not be explained only by the arterial hypertension because their blood pressure values were not different than those of the control group. The results suggest that the three [beta]-blockers tested play a direct effect for lowering pain scores. The dose-effect correlation observed in the atenolol, but not in propranolol patient group, could be explained by [[beta].sub.1] selectivity, blood-brain barrier impermeability and less membrane stabilizing effect for atenolol. The current study confirms previous findings about the role of [beta]-adrenergic receptors in nociception (12, 13), based on decrease of the adenylcyclase activity (25), reduction of intracellular AMPc and inhibition of voltage sensitive calcium and sodium channels activity (12, 13, 26), which lead to a decrease of neuronal excitability. Additionally, [beta]-blockers are able to suppress IL-6 (27) and TNF[alpha] (28) release and to inhibit the phospholipase A (29), all these actions are strongly linked to analgesia (7).

Like the results from patients with [beta]-blockers therapy, neither systolic nor diastolic blood pressure from patients with amlodipine therapy was different to those from the control group. Thus, the possible contribution of blood pressure values to reduce pain sensation should be marginal vide supra. The analgesic effect observed in patients receiving amlodipine agrees with previous reports, that support the notion that voltage sensitive calcium channel blockers decrease neuronal excitability, by means of reducing calcium influx by a dose-response effect (30). Neurons with a wide variety of calcium channels in their cellular membrane have been described in nociceptive pathways and centers (31), playing an important role for sensitization and potentiation of nociceptive neurons and their neuronal network (8, 9). The clinical results of the present study confirms previous findings about the relevant role of voltage sensitive calcium channels in human nociception (3, 7, 31).

The group of patients with digoxin therapy shows the higher values of subjective intensity to mechanical noxious stimulus. The digoxin-induced inhibition of the Na/K ATPase, not only in the heart, but also in neurons, leads to an increase of the intracellular sodium concentrations, which depolarizes the neuron, increases their excitability (6, 14, 16) and opens voltage sensitive calcium and sodium channels with a strong neuronal depolarization (7). Neuronal depolarization and release of excitatory amino acid are mimicked by ouabain (32). Consistently, well known analgesic substances like morphine and encephaline analogues significantly increase Na/K ATPase activity; on the other hand, the opiate antagonist, naloxone, decreased the activity of Na/K ATPase (33). However, the effect of ouabain is not completely clear. Spinal intrathecally administered ouabain has been reported to produce antinociception via an enhancement of cholinergic transmission in the spinal nociceptive processing system (34), but intracerebroventricular application of ouabain antagonizes opioid analgesia, which suggests its effect on supraspinal Na/K-ATPase (17).

It is well known that blood levels of interleukins IL-6 and TNF[alpha] rise in patients with heart failure showing a direct correlation between their blood concentration and the heart failure grade (35). These products exert a clear proinflammatory and proalgesic effects (36) which could contribute to the increased subjective pain intensity rates of the digoxin/heart failure patient group; however, this group, were all clinically stable, condition associated to low increases of blood concentrations of IL-6 and TNF[alpha] (37, 38). Moreover, the age related increase of these cytocines was reported particularly in patients over 85 years of age (39). The age of the digoxin patient group evaluated in the present study was 15 years younger, but the role of age related increase of cytocines cannot be ruled out, together with the ATPase inhibition induced by digoxin to explain the increased subjetive pain intensity reported by the patient group. However, since cytokines levels were not measured in the current study, the influence of cytokines in the digoxin/ heart failure patient group can not be proven.

Circulating Na, K-ATPase inhibitory and digoxin-like immunoreactivity factors have been reported increased in patients with heart failure (40, 41), but once again, the clinically stable status for the digoxin/ heart failure patient group, strongly suggests that the main contribution for the hyperalgesia is made by digoxin. However, it cannot completely ruled out that patients receiving digoxin were age and co-morbidity different to the control group. The cross-sectional design of the study raises some limitations about homogeneity between the control and digoxin groups.

The group receiving amlodipine showed a higher analgesic effect than the [beta]-blockers therapy group, i.e., propranolol, atenolol or pindolol, which suggests a greater effect of the calcium ion and its voltage sensitive channels over the stabilizing membrane effect produced by the [beta]-adrenergic receptor blockers for mechanical noxious stimulation.

The significant reduction of VA[S.sub.2] over VAS1 values ranged between -7% to -21% observed at least 5 minutes after the first (conditioning) noxious stimulation which agrees with pain modulation system activation (42, 43), was differentially affected by the voltage sensitive calcium channel blocker amlodipine, [beta]-adrenergic receptor blockers, i.e., propranolol, atenolol and pindolol, but not by the ATPase inhibitor digoxin, these different pharmacological responses confirms that in pain modulation systems, which includes spinal and supra-spinal mechanisms, both calcium channels and [beta]-adrenergic receptors blockers play a fundamental role with a major effect of the calcium channels as shown intra and intergroup [DELTA]VAS values of the present study, with no influence of the treatment time.

Despite that results confirm and agree with previous basic and clinical findings, the cross sectional experimental design and the use of healthy volunteers as a control group, that make possible the present study, also generate difficulties in the interpretation of the results because it is no possible to determine whether the found changes in nociception are due to the treatment or to the underlying pathology of the subjects.

Arterial hypertension and heart failure are common morbility that affects at least 20% of the population. The present study suggests the influence on nociception of widely used drugs in these cardiovascular diseases, showing that calcium channel and [beta]-adrenergic receptors blockers, could decrease and digoxin could increase pain sensation. The clinical possibility to use both mechanisms, such as a synergic antinociceptive action must be further tested, based on the advantage of current available calcium channel and adrenergic receptors blockers, but careful analysis of the effects on cardiovascular parameters like blood pressure are needed.

ACKNOWLEDGEMENTS

The authors thank Vivas-O'Connor V. and Tucci M. for helpful comments. Supported by Grant from the Consejo de Desarrollo Cientifico y Humanistico, CDCH-UC, Universidad de Carabobo, Venezuela.

REFERENCES

(1.) Koella WP. CNS-related side-effects of beta-blockers with special reference to mechanisms of action. Eur J Clin Pharmacol 1985; 28:55-63.

(2.) Miljanich GP, Ramchandran J. Antagonists of neuronal calcium channels: structure, function and implications. Annu Rev Pharmacol Toxicol 1995; 35:707-734.

(3.) Brose WG, Gutlove DP, Luther RR, Bowersox SS, McGuire D. Use of intra thecal SNX-111, a novel, n-type, voltage-sensitive, calcium blocker, in the management of intractable brachial plexius avulsion. Clin J Pain 1997; 13:256-257.

(4.) Diaz A, Dickenson AH. Blockade of spinal n-type and p-type but not l-type calcium channels excitability of rat dorsal horn neurones produced by subcutaneous inflammation ity of rat dorsal horn neurones produced by subcutaneous inflammation. Pain 1997; 69:93-100.

(5.) Martin MI, del Val VL, Colado MI, Goicoechea C, Alfaro MJ. Behavioral and analgesic effects induced by administration of nifedipine or nimodipine. Pharmacol Biochem Behav 1996; 55:93-98.

(6.) Li S, Stys PK. Na+-K+-ATPase inhibition and depolarization induce glutamate release via reverse Na+-dependent transport in spinal cord white matter. Neuroscience 2001; 107:675-683.

(7.) Millan MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164.

(8.) Willis WD, Coggeshall RE. Sensory Mechanisms of the Spinal Cord. First Edn. New York: Springer, 1991.

(9.) Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental allodynia. J Pharmacol Exp 1994; 269:1117-1123.

(10.) Dogrul A, Bilsky EJ, Ossipov MH, Lai J, Porreca F. Spinal L-Type Calcium Channel Blockade Abolishes Opioid-Induced Sensory Hypersensitivity and Antinociceptive Tolerance. Anesth Analg 2005; 101:17301735.

(11.) Doggrell SA. The membrane stabilizing and beta 1-adrenoceptor blocking activity of +- and -propranolol on the rat left atria. Gen Pharmacol 1990; 21:677-80.

(12.) Matthews JC, Baker JK. Effects of propranolol and a number of its analogues on sodium channels. Biochem Pharmacol 1982; 31:1681-1685.

(13.) Akaike N, Ito H, Nishi K, Oyama Y. Further analysis of inhibitory effects of propranolol and local anaesthetics on the calcium current in Helix neurones. Br J Pharmacol 1982; 76:37-43.

(14.) Czaplinski M, Abad C, Eblen-Zajjur A. Normal expression and Inflammation-induced changes of Na and Na/K ATPase activity in spinal dorsal horn of the rat. Neurosci Lett 2004; 374:147-151.

(15.) Glykys J, Guadama M, Ochoa E, Marcano L, Eblen-Zajjur A. Inflammation induced increase of fluoride resistant acid phosphatase FRAP activity in the spinal dorsal horn in rats. Neurosci Lett 2003; 337:167-169.

(16.) Schwinger RH, Bundgaard H, MullerEhmsen J, Kjeldsen K. The Na, K-ATPase in the failing human heart. Cardiovasc Res 2003; 57:913-920.

(17.) Masocha W, Horvath G, Agil A, Ocana M, Del Pozo E, Szikszay M, Baeyens JM. Role of Na(+), K(+)-ATPase in morphine-induced antinociception. J Pharmacol Exp Ther. 2003; 306:1122-1128.

(18.) Villanueva L. Diffuse Noxious Inhibitory Control (DNIC) as a tool for exploring dysfunction of endogenous pain modulatory systems. Pain. 2009; 143:161-2.

(19.) Sandkuhler J, Stelzer B, Fu QG. Characteristics of propriospinal modulation of nociceptive lumbar spinal dorsal horn neurons in the cat. Neuroscience. 1993; 54: 957-967.

(20.) Bee LA, Dickenson AH. Rostral ventromedial medulla control of spinal sensory processing in normal and pathophysiological states. Neuroscience. 2007; 147: 786-793.

(21.) Lugo M, Isturiz G, Lara C, Garcia N, Eblen-Zajjur A. Sensory lateralization in pain subjective perception for noxious heat stimulus. Somatosens Mot Res 2002; 19:207-212.

(22.) Zamir N, Segal M. Hypertension-induced analgesia: changes in pain sensitivity in experimental hypertensive rats. Brain Res. 1979; 160:170-173.

(23.) Ghione S. Hypertension-associated hypalgesia, Evidence in experimental animals and humans, pathophysiological mechanisms, and potential clinical consequences. Hypertension 1996; 28:494-504.

(24.) Rosa C, Vignocchi G, Panattoni E, Rossi B, Ghione S. Relationship between increased blood pressure and hypoalgesia: additional evidence for the existence of an abnormality of pain perception in arterial hypertension in humans. J Hum Hypertens 1994; 8:119-126.

(25.) Taussing R, Gilman AG. Mammalian membrane-bound adynylyl cyclase. J Biol Chem 1995; 270:1-4.

(26.) Brown AM, Birnbaumer L. Direct G protein gating of ion channels. Am J Physiol 1988; 254:H401-H410.

(27.) Soszynski D, Kozak W, Conn CA, Rudolph K, Kluger MJ. Beta-adrenoceptor antagonists suppress elevation in body temperature and increase plasma IL-6 in rats exposed to open field. Neuroendocrinology1996; 63:459-467.

(28.) Bloksma N, Hofhuis F, Benaissa-Trouw B, Willers J. Endotoxin-induced release of tumour necrosis factor and interferon in vivo is inhibited by prior adrenoceptor blockade. Cancer Immunol Immunother 1982; 14:41-45.

(29.) Trotz M, Jellison EJ, Hostetler KY. Propranolol inhibition of the neutral phospholipase A of rat heart mitochondria, sarcoplasmic reticulum and cytosol. Biochem Pharmacol 1987; 36:4251-4256.

(30.) Sluka KA. Blockade of calcium channels can prevent the onset of secondary hyperalgesia and allodynia induced by intradermal injection of capsaicin in rats. Pain 1997; 71:157-164.

(31.) Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52:259-285.

(32.) Rosen AS, Morris ME. Depolarizing effects of anoxia on pyramidal cells of rat neocortex. Neurosci Lett 1991; 124:169-173.

(33.) Hajek I, Teisinger J, Sykova E. The effect of opioids and of naloxone on Na+, [K.sup.+]-adenosine triphosphatase activity in frog spinal cord membrane fractions. Neurosci Lett 1985; 59:291-295.

(34.) Zeng W, Dohi S, Shimonaka H, Asano T. Spinal antinociceptive action of Na+-K+ pump inhibitor ouabain and its interaction with morphine and lidocaine in rats. Anes thesiology1999; 90:500-508.

(35.) Gwechenberger M, Hulsmann M, Berger R, Graf S, Springer C, Stanek B, Pacher R. Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 2004; 23:839-844.

(36.) Cunha FQ, Ferreira SH. Peripheral hyperalgesic cytokines. Adv Exp Med Biol 2003; 521:22-39.

(37.) Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol 2004; 94:249-251.

(38.) Wykretowicz A, Furmaniuk J, Smielecki J, Deskur-Smielecka E, Szczepanik A, Banaszak A, Wysocki H. The oxygen stress index and levels of circulating interleukin10 and interleukin-6 in patients with chronic heart failure. Int J Cardiol 2004; 94:283-287.

(39.) Mariani E, Cattini L, Neri S, Malavolta M, Mocchegiani E, Ravaglia G, Facchini A. Simultaneous evaluation of circulating chemokine and cytokine profiles in elderly subjects by multiplex technology: relationship with zinc status. Biogerontology 2006; 7:449-459.

(40.) Bagrov AY, Fedorova OV, Maslova MN, Roukoyatkina NI, Ukhanova MV, Zhabko EP. Endogenous plasma Na,K-ATPase inhibitory activity and digoxin like immunoreactivity after acute myocardial infarction. Cardiovasc Res 1991; 25:371-377.

(41.) Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino MC, Montali U, Labbate A. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 2001; 3:165-171.

(42.) Eblen-Zajjur A, Salas R, Vanegas H. Fractal analysis of spinal nociceptive neuronal responses to receptive field stimulation and to heterotopic noxious stimulation in the rat. Neurosci Res Comm 1999; 25:51-60.

(43.) Willer JC, Roby A, Le Bars D. Psycho physical and electrophysiological approaches to the pain-relieving effects of heterotopic nociceptive stimuli. Brain 1984; 107:1095-1112.

Alfredo Del Giaccio [1], Antonio Eblen-Zajjur [2]

[1] Servicio de Medicina Interna, Hospital Universitario "Dr. Angel Larralde", Instituto Venezolano de los Seguros Sociales y

[2] Departamento de Ciencias Fisiologicas, Facultad de Ciencias de la Salud, Universidad de Carabobo, Valencia, Venezuela.

Corresponding author: Antonio Eblen-Zajjur. Facultad de Ciencias de la Salud, Universidad de Carabobo, P.O. Box 3798, El Trigal. Valencia, Venezuela. E-mail: aeblen@uc.edu.ve.
TABLE I

SAMPLE SIZE, AGE, RANGE AND STATISTICAL COMPARISON AMONG
DIFFERENT PATIENT AND CONTROL GROUPS

Group             n    Age (years)            Range    P

Control           60   43.34 [+ or -] 15.22   21-84
[beta]-blockers   45   44.11 [+ or -] 12.23   24-79    ns
Amlodipine        40   47.23 [+ or -] 11.66   28-73    ns
Digoxin           70      35 [+ or -] 7.03    45-86    **

X [+ or -] SD.   ** P<0.0000001.   ns: P>0.01 (against Control).

TABLE II

PATIENT DISTRIBUTION IN THE [beta]-BLOCKERS GROUP ACCORDING
TO THE DRUG AND COMPARISON BETWEEN THEIR VAS VALUES

              Propranolol          Atenolol

n             13                   25
[VAS.sub.1]   3.57 [+ or -] 0.80   3.45 [+ or -] 1.00
[VAS.sub.2]   2.92 [+ or -] 0.92   2.88 [+ or -] 0.86

              Pindolol             P

n             7
VA[S.sub.1]   3.94 [+ or -] 1.11   >0.27
VA[S.sub.2]   3.50 [+ or -] 1.26   >0.13

VAS values are X [+ or -] SD; P is the best value of
all pair tests from the three groups.

TABLE III

DISTRIBUTION AND VAS VALUES OF CONTROL SUBJECTS, PATIENTS
WITH ARTERIAL HYPERTENSION OR ARTERIAL HYPERTENSION
INDUCED HEART FAILURE

Patients   n    [VAS.sub.1]               %

Controls   60   5.64 [+ or -] 1.50      -42.55
AH         85   3.24 [+ or -] 1.05 **   +57.44
AH + HF    40   8.88 [+ or -] 1.27 **   +174.07 **

Patients   %            [VAS.sub.2]              %

Controls   -42.55       5.21 [+ or -] 1.44      -49.32
AH         +57.44       2.64 [+ or -] 1.07 **   +58.54
AH + HF    +174.07 **   8.26 [+ or -] 1.13 **   +212.88 *

AH: arterial hypertension (n=85). HF: heart failure (n=40).
Values are X [+ or -] SD.

* P<0.001. ** P<0.0000001. Last row of % is the differences
between AH+HF group and AH group.

TABLE IV

VAS VALUES, ANALGESIC INDEX, PERCENTAGE OF CHANGE AND T-TEST
FOR THE STUDIED GROUPS

                          Control             [beta]-blockers

n                         60                  45
[VAS.sub.1]               5.63 [+ or -] 1.49   3.56 [+ or -] 0.95
[DELTA] group (%)                             -36.8 **

[VAS.sub.2]               5.17 [+ or -] 1.45   2.98 [+ or -] 0.94
[DELTA] group (%)                             -42.4 **
[DELTA] [VAS.sub.1-2](%)  -6.13 *             -16.28 **

                          Amlodipine          Digoxin

n                         40                  40
VA[S.sub.1]               2.78 [+ or -] 0.92   8.81 [+ or -] 0.92
[DELTA] group (%)         -50.6 **            +56.5 **

VA[S.sub.2]               2.18 [+ or -] 1.00   8.19 [+ or -] 1.21
[DELTA] group (%)         -57.8 **            +58.4 **
[DELTA] VA[S.sub.1-2](%)  -23.78 **           -6.93 (ns)

VAS values are X [+ or -] SD. All reported P values are control group
comparison. Agroup (%) are differences between that particular
VAS group value against the control group (100%), negative
values means analgesia and positive values means hyperalgesia.
For [DELTA] [VAS.sub.1-2], [VAS.sub.1] was considered 100%.

* P=0.0003. ** P=0.0000001. ns=P<0.01.
COPYRIGHT 2010 Universidad del Zulia
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Author:Del Giaccio, Alfredo; Eblen-Zajjur, Antonio
Publication:Investigacion Clinica
Date:Mar 1, 2010
Words:4421
Previous Article:La Proteina C Reactiva se asocia al grosor de la intima media de la arteria carotida en pacientes con hipercolesterolemia aislada.
Next Article:Evaluacion de la calidad del espermatozoide humano: comparacion entre la integridad del ADN espermatico y variables del semen.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters